Unibest
← Back to patent-cliff list

CAS 1282513-03-4

2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid

Codes: TASE-023

Application context (from source-drug indications)

Breast cancerTaselisibBladder cancerTaselisibMultiple myelomaTaselisibLung cancerTaselisibLiver cancerTaselisibCervical cancerTaselisib

Source drugs (routes using this intermediate)

DrugTierExpiry
TaselisibTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.